CloneID: MEDI-579
Antigen Long Description: The original antibody was isolated from a human scFv library by panning on recombinant human and rat PAI-1 followed by screening in a PAI-1/tPA competition binding assay.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P05121
Specificity Statement: This antibody binds the reactive center loop (RCL) of human PAI-1 and at the same exosite used by both tissue and urokinase plasminogen activators (tPA and uPA). This antibody binds the active form of human PAI-1. Plasminogen activator inhibitor-1 (PAI-1), is a serine protease inhibitor, a unique member of the serpin superfamily which plays an important role in fibrinolysis and is an established risk factor for cardiovascular diseases. It a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading .
Application Notes (Clone): This antibody specifically inhibits serine protease interactions with PAI-1 while conserving vitronectin binding. The binding of this antibody to native and latent form of human PAI-1 was determined using ELISA. This antibody was able to neutralize recombinant human, rat and mouse PAI-1 activity in species-relevant tPA-coupled chromogenic assays. The Fab version of this antibody binds human and rat PAI-1 with a binding affinity (Kd) of 5.34 pM and 84 pM respectively. Competition binding experiments also demonstrates that MEDI-579 does not interact with other circulating serpins (PMID: 30733557). This antibody is effective in slowing the progression of diabetic nephropathy in db/db mice and that the effect is additive to ACEI (PMID: 27511457).
English
Deutsch
